Insulet Corporation Announces Pricing of Initial Public Offering

BEDFORD, Mass., May 15, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insulet Corporation, (Nasdaq: PODD) today announced the pricing of its initial public offering of 7,700,000 shares of common stock at $15.00 per share. Shares of Insulet's common stock will begin trading on the Nasdaq Global Market today, under the symbol "PODD." All shares in the offering are being sold by Insulet. Insulet has granted to the underwriters an option to purchase up to 1,155,000 additional shares of its common stock at the public offering price to cover any over-allotments.

J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as joint book-running managers, and Thomas Weisel Partners LLC and Leerink Swann & Co., Inc. acted as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of the written prospectus forming part of the effective registration statement.

A copy of the prospectus relating to the offering may be obtained by contacting one of the following:

J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002.

Merrill Lynch, Pierce, Fenner & Smith Incorporated, World Financial Center, 250 Vesey Street, New York, NY 10080 or by calling (212) 449-1000.

About Insulet Corporation

Founded in 2000, Insulet Corporation is a medical device company located in Bedford, Massachusetts. The company seeks to improve the lives of people with diabetes and expand the use of continuous subcutaneous insulin infusion (CSII) therapy through innovative technology and feedback from people with diabetes and healthcare professionals. Insulet Corporation develops, manufactures and markets the OmniPod Insulin Management System, an innovative, discreet and easy-to-use insulin infusion system for people with insulin- dependent diabetes.

For more information about Insulet Corporation and the OmniPod System, please visit our website at www.insulet.com.

SOURCE Insulet Corporation

Stephanie Marks for Insulet Corporation, 877-PODD-IR1 877-763-3471, ir@insulet.com

http://www.insulet.com/